Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human BTLA (31-134) Protein, Fc Tag, 100µg  

Recombinant Human BTLA (31-134) Protein, Fc Tag, 100µg

Recombinant Human BTLA (31-134) Protein, Fc Tag, AA Lys 31 - Thr 134, was produced in human 293 cells (HEK293).

Synonym: recombinant, human, protein, BTLA,CD272

More details

BTA-H5255-100

Availability: within 7 days

455,00 €

Background
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Source
Recombinant Human BTLA, Fc Tag (BTA-H5255) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Thr 134 (Accession # NP_001078826.1).
Predicted N-terminus: Lys 31

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 38.7 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>92% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Correction to: BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer"
Diskin, Adam, Soto et al
Oncogene (2023)
(2) "Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion"
Salnikov, Prusinkiewicz, Lin et al
Viruses (2023) 15 (1)
(3) "B and T lymphocyte attenuator as a C-reactive protein and IgA associated auxiliary diagnostic marker for pulmonary tuberculosis: a case-control study"
Xu, Bian, Wang et al
Ann Transl Med (2022) 10 (24), 1370
Showing 1-3 of 607 papers.